FindTrial
Sign In

Placebo (PB)

DRUG4 trials

Sponsors

UCB Pharma, Regeneron Pharmaceuticals

Conditions

Amyotrophic Lateral Sclerosis (ALS)Epilepsy, PartialHealthy VolunteersHealthy Volunteers With HyperlipidemiaMetabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)Mutation in the Superoxide Dismutase-1 (SOD1) Gene

Phase 1

A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
RecruitingNCT05648214
Regeneron PharmaceuticalsHealthy Volunteers, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Start: 2022-12-27End: 2027-08-10Target: 156Updated: 2025-12-22
First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)
RecruitingNCT06351592
Regeneron PharmaceuticalsAmyotrophic Lateral Sclerosis (ALS), Mutation in the Superoxide Dismutase-1 (SOD1) Gene
Start: 2024-08-28End: 2031-06-05Target: 42Updated: 2026-02-27
A First In Human (FIH) Study to Learn if Different Doses of ALN-ANG3 Are Safe and Well Tolerated in Healthy Adults
Active, not recruitingNCT06452771
Regeneron PharmaceuticalsHealthy Volunteers With Hyperlipidemia
Start: 2024-06-27End: 2026-12-04Updated: 2026-02-20

Phase 2

A 19-week Cognition Study of Levetiracetam in Children With Partial Onset Seizures
CompletedNCT00105040
UCB PharmaEpilepsy, Partial
Start: 2004-09-30End: 2007-03-31Updated: 2015-03-02

Related Papers

Assessment of behavioral and emotional functioning using standardized instruments in children and adolescents with partial-onset seizures treated with adjunctive levetiracetam in a randomized, placebo-controlled trial.
2010-05-2329 citations